Topic: blood collection device
Sight Diagnostics, maker of point-of-care blood diagnostic hardware, raised $27.8 million to continue its expansion and fund U.S. regulatory efforts.
Velano Vascular’s mission is to improve the hospital experience for patients and healthcare providers by reducing the pain and risk associated with drawing blood.
Seventh Sense Biosystems (7SBio) concentrates on revolutionizing blood collection with a device that is easy and painless to use.
The deal connects Ionis to the manufacturer of a blood collection device that could simplify mitigation of its drugs’ safety risks.
Intermountain Health is the first health system to adopt Velano's PIVO technology, eliminating needle sticks from blood collection.
Velano Vascular raised $17 million in financing, which it will put toward scaling and commercializing its line of vascular access devices.
The FDA cleared Velano Vascular’s second iteration of its needle-free blood draw device, which attaches to the peripheral IV line that most hospital patients already have.
Seventh Sense Biosystems picked up an FDA nod for its “push-button” blood collection device, specifically to test the HbA1c levels in patients with diabetes and prediabetes. The company plans to add more assays for use with the device.
Sacramento’s Sutter Health is piloting Velano Vascular’s needle-free blood draw technology. It is among the first health systems in the country to offer the tech, which is based on the peripheral IV line that most in-patients already have.
Seventh Sense Biosystems picked up a $10 million Series C to develop new products around and to expand manufacturing capacity for its “push-button” blood collection device.